GRFS has been the subject of a number of other research reports. Citigroup upgraded Grifols from a sell rating to a neutral rating in a report on Thursday, October 1st. Morgan Stanley restated an overweight rating on shares of Grifols in a report on Wednesday, December 9th. Zacks Investment Research cut Grifols from a buy rating to a hold rating in a report on Wednesday, November 4th. Finally, Berenberg Bank restated a buy rating on shares of Grifols in a report on Friday, October 30th. Two analysts have rated the stock with a sell rating, five have issued a hold rating and three have issued a buy rating to the company. The stock has an average rating of Hold and a consensus target price of $20.00.
Grifols stock opened at $18.44 on Wednesday. Grifols has a 52 week low of $13.40 and a 52 week high of $25.73. The company has a debt-to-equity ratio of 0.95, a quick ratio of 1.33 and a current ratio of 2.93. The stock has a market capitalization of $12.68 billion, a P/E ratio of 16.46, a PEG ratio of 1.44 and a beta of 0.61. The stock has a 50-day simple moving average of $18.81 and a 200 day simple moving average of $18.14.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in GRFS. RMR Wealth Builders acquired a new stake in shares of Grifols in the second quarter valued at approximately $35,000. Signaturefd LLC raised its position in Grifols by 102.8% during the third quarter. Signaturefd LLC now owns 2,995 shares of the biotechnology company’s stock valued at $52,000 after purchasing an additional 1,518 shares in the last quarter. Canton Hathaway LLC acquired a new position in Grifols during the third quarter valued at approximately $68,000. PNC Financial Services Group Inc. raised its position in Grifols by 70.8% during the second quarter. PNC Financial Services Group Inc. now owns 6,916 shares of the biotechnology company’s stock valued at $126,000 after purchasing an additional 2,867 shares in the last quarter. Finally, Harding Loevner LP raised its position in Grifols by 9,180.4% during the third quarter. Harding Loevner LP now owns 9,002 shares of the biotechnology company’s stock valued at $157,000 after purchasing an additional 8,905 shares in the last quarter. Institutional investors own 15.10% of the company’s stock.
Grifols Company Profile
Grifols, SA develops, manufactures, and distributes a range of biological medicines on plasma derived proteins worldwide. The company operates in five segments: Bioscience, Diagnostic, Hospital, Bio Supplies, and Others. The Bioscience segment manufactures plasma derivatives for therapeutic use; and sells and distributes end products.
See Also: What is a closed-end mutual fund (CEF)?
Receive News & Ratings for Grifols Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Grifols and related companies with MarketBeat.com's FREE daily email newsletter.